BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Eisai Turns Over Majority of Aduhelm Rights to Biogen

  Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).

  March 15, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Coherus, Junshi Tout Positive Results in NSCLC

  A checkpoint inhibitor under development by China’s Junshi Biosciences and Coherus BioSciences hit the mark in a Phase III lung cancer study.

  March 15, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Life Sciences Industry Emphasizes Growth, Purpose in Fight for Talent

  According to a recent BioSpace report, the top three motivators for employees to look for a new job are growth opportunities, greater compensation and the desire for a new challenge.

  March 15, 2022

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Report Highlights the High Economic Burden of Rare Diseases

  For the United States, the total economic burden of rare disease is estimated to be $2.2 trillion per year.

  March 15, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Passage Bio Culls 13% of Headcount, Prioritizes Gene Therapy

  Less than one week after dosing the first patient in a Phase I/II gene therapy trial for early infantile Krabbe disease, Passage Bio announced it was cutting its headcount by 13% in order to preserve cash runway.

  March 15, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Nutcracker, RefleXion Score Fresh Funds for Oncology Innovation

  Two oncology-focused biotechnology firms generated a total of $247 million in additional funding to support their respective research and development efforts for cancer treatment.

  March 15, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Moderna Takes on Biggest Target Yet, Launching 2nd HIV Trial

  Moderna announced that the first participant has been dosed in a Phase I trial of its HIV trimer mRNA vaccine, mRNA-1574.

  March 15, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Nektar Left Reassessing After Canceled Melanoma Trials

  After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.

  March 15, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Astellas Feels the Heat as Menopause Vasomotor Symptoms Therapy Misses in China

  The investigational oral drug for vasomotor symptoms in menopause women couldn’t meet the pre-defined efficacy. Here’s how it performed during the clinical stages.

  March 15, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Career Advice

  Undergraduate Pharmaceutical Degree Options That Won’t Break the Bank

  Finding the most cost-effective school for your undergraduate pharmaceutical degree can allow you to start working in the field without incurring astronomical student debt.

  March 15, 2022

   · 

  4 min read

   · 

  Karen Walpole